Skip to content Skip to footer
Subscribe Now
NEWS

Amberstone and Henlius Partner to Develop Conditionally Activated T-Cell Engagers for Solid Tumors

Shots: Amberstone Biosciences has entered into a collaboration & license agreement with Henlius Biotech to advance conditionally activated T-cell engagers for the treatment of solid tumors As per the deal, Amberstone will use its T-MATE platform to generate preclinical candidates against ~2 Henlius-selected targets, while Henlius will lead subsequent research, development, manufacturing & global commercialization…
1 day ago

Read more

NEWS

BoomRay Inks a ~$900M Deal with Novartis for a Novel RLT Asset

Shots: Boomray Pharmaceuticals has entered into an exclusive global license agreement with Novartis for an undisclosed preclinical radioligand therapy (RLT) asset As per the deal, BoomRay will receive ~$900M, incl. an upfront payment as well as development, regulatory, & sales milestone payments, with royalties on future global net sales Agreement combines BoomRay’s discovery & development capabilities…
4 days ago

Read more

NEWS

mAbxience and Sandoz Partner to Advance Emicizumab Biosimilar Access Globally

Shots: mAbxience & Sandoz have entered into a licensing, development, manufacturing & commercialization agreement for an emicizumab biosimilar candidate As pe the deal, mAbxience will develop & manufacture the biosimilar at its GMP-approved facilities in Spain & Argentina, while Sandoz will hold exclusive global commercialization rights (excl. Argentina, Uruguay & Paraguay); financial terms remain confidential…
September 21, 2026

Read more

NEWS

1ST Biotherapeutics Inks ~$314.8M Deal with SK Biopharmaceuticals for 1ST-104

Shots: 1ST Biotherapeutics SK Biopharmaceuticals have entered into an exclusive global licensing agreement & strategic equity investment partnership to advance 1ST-104 for the treatment of Parkinson's disease  As per the deal, 1STBIO will receive a $1.8M upfront payment, with the licensing agreement valued at ~$314.8M, incl. a $1.8M short-term milestone upon candidate selection & additional…
September 18, 2026

Read more

NEWS

Orbis Medicines and Novo Partner on Oral Macrocycle Drugs in a ~$1.4B Deal

Shots: Orbis Medicines has entered into a strategic collaboration & license agreement with Novo to discover & develop next-generation oral macrocycle therapeutics for cardiometabolic diseases  As per the deal, Orbis will receive ~$1.4B in upfront, and development & commercial milestone payments, plus tiered royalties on future product sales, while Novo will also make a strategic…
September 17, 2026

Read more

NEWS

Dualitas Therapeutics and Roche Partner to Advance Novel Bispecific Antibodies for I&I Diseases in a ~$1B Deal

Shots: Dualitas has entered into a research collaboration & license agreement with Roche to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases, using Dualitas' DualScreen Bispecific Discovery Engine As per the deal, Dualitas will receive $36.5M upfront & additional research, development & commercial milestone payments, representing the total deal value of ~$1B, in addition…
September 17, 2026

Read more

Load more